Key Corporate Partnerships

In 2018, we entered into non-exclusive global collaboration agreements with Junshi and Innovent to conduct  safety  run-in  studies  to  evaluate  the  safety  of fruquintinib or surufatinib  in combination with PD-1 monoclonal antibodies being developed by Junshi (Tuoyi) and Innovent (Tyvyt)